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STATEMENTS 
What is already known about the topic? The emergence of severe-acute-respiratory-
syndrome coronavirus 2 (SARS-CoV-2) and its consequences during pregnancy have led to an 
increasing volume of data about the maternal and fetal outcomes of SARS-CoV-2 infections.  
What does this study add? This review summarizes maternal and fetal outcomes found in the 
literature as of April 22, 2020. This review also provides an overview of current candidate 
therapeutic options during pregnancy and clinical guidelines for prenatal management of 
COVID-19 affected pregnancies.  
 
Data Availability Statement: Research data are not shared. 
 
Short title: Coronaviruses and pregnancies 
 
Keywords: Coronavirus, MERS, SARS-CoV, COVID-19, pregnancy, adverse maternal 
outcomes 
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ABSTRACT 
Since December 2019, the novel SARS-CoV-2 outbreak has resulted in millions of cases and 
more than 200,000 deaths worldwide. The clinical course among non-pregnant women has been 
described but data about potential risks for women and their fetus remain scarce. The SARS 
and MERS epidemics were responsible for miscarriages, adverse fetal and neonatal outcomes 
and maternal deaths. For COVID-19 infection, only 9 cases of maternal death have been 
reported as of April 22, 2020 and pregnant women seem to develop the same clinica l 
presentation as the general population. However, severe maternal cases, as well as prematurity, 
fetal distress and stillbirth among newborns have been reported. The SARS-CoV-2 pandemic 
greatly impacts prenatal management and surveillance and raise the need for clear unanimous 
guidelines. In this narrative review, we describe the current knowledge about coronaviruses 
(SARS, MERS and SARS-CoV-2) risks and consequences on pregnancies and we summarize 
available current candidate therapeutic options for pregnant women. Finally, we compare 
current guidance proposed by RCOG, ACOG and the WHO to give an overview of prenatal 
management which should be utilized until future data appear.  
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INTRODUCTION 
In December 2019, multiple cases of pneumonia of unknown origin were reported in the 
Province of Wuhan, China and rapidly attributed to a novel coronavirus, closely related to the 
2003 severe acute respiratory syndrome (SARS-CoV) and therefore named the severe acute 
respiratory syndrome 2 (SARS-CoV-2). This new virus spread throughout China and rapidly 
covered the globe causing over 2 million cases and more than 200,000 deaths within the recent 
months. The World Health Organization (WHO) declared this outbreak a pandemic on March 
11, 2020 (Figure 1). 
Although numerous reports have described the clinical course of COVID-19 among non-
pregnant patients, data regarding pregnant women remain scarce (1)(2). Recent outbreaks of 
emerging infections have highlighted their potential impact on pregnant women and/or their 
fetus, such as the 2009 H1N1 influenza pandemic (3) or more recently, the Zika virus outbreak 
in the Americas (4). As information regarding this novel coronavirus is lacking, data on SARS-
CoV-1 (2003) and MERS-CoV (Middle East respiratory syndrome, 2012) may help us 
understand the potential risks for pregnancy in the context of COVID-19. In this narrative 
review, we described the current knowledge (up to April 22, 2020) about the risks and 
consequences of SARS-CoV-2 on pregnant women and their babies and compare them to SARS 
and MERS. Because therapeutic options and clinical management remain unclear, we 
summarize information about treatments that have been tried or could be considered for 
COVID-19 affected pregnancies. Finally, we compare current guidelines proposed by the 
RCOG, ACOG and WHO to give an overview of prenatal management which should be utilized 
until future data are available.  
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METHODS 
A PubMed search was carried out using the terms “Coronavirus 2 and pregnancy”, “SARS-
CoV-2 and pregnancy”, “SARS and pregnancy” and “MERS and pregnancy” that identified 
447 articles published before April 22, 2020 (Figure 2 & 3). We reviewed all titles and abstracts 
when available, and limited the search to articles reporting maternal infections, fetal and 
perinatal outcomes and clinical management. Guidelines providing recommendations for 
management of COVID-19 pregnancies were also included. At least two reviewers evaluated 
the articles and extracted data. Searches were limited to the English language. The process of 
article selection and the number of articles are described figure 3. 
 
 
BACKGROUND: VIROLOGY AND EPIDEMIOLOGY OF EMERGING 
CORONAVIRUSES 
Coronaviridae is a large family of single-stranded RNA, non-segmented and enveloped viruses. 
Though most of them cause benign disease, we have recently experienced the emergence of 
three novel coronaviruses associated with alarmingly high mortality rates: the Severe Acute 
Respiratory Syndrome Coronavirus 1 (SARS-CoV-1) in 2003, the Middle East Respiratory 
Syndrome Coronavirus (MERS-CoV) in 2011 and most recently the SARS-CoV-2 in 2020.  
These viruses are members of the betacoronavirus genus and have all arisen from anima l 
reservoirs (i.e. zoonosis), namely bats for SARS-CoV and SARS-CoV2, and camels for MERS-
CoV. The newly acquired human-to-human transmission allowed for their rapid dispersion, 
causing epidemics and pandemics among naïve populations (5). Human-to-human transmiss ion 
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occurs via droplets and fomites. Though transmission through aerosols has been demonstrated 
in laboratory conditions (6), its public health relevance remains highly debated. Recent data 
have demonstrated the efficacy of contact and droplet protection measures among hospitalized 
staff, suggesting the lack of significant aerosol transmission. (7) 
SARS-CoV-1 presented as a novel atypical pneumonia in Hong Kong in June 2003. More than 
8,000 individuals were infected around the world and the overall case fatality rate (CFR) was 
estimated to be around 11% according to the WHO (8). Drastic infectious disease control 
measures halted the epidemic and no cases have been reported since 2004 (5). 
Later in 2012, MERS-CoV emerged in the Middle East. Infected individuals exhibited a severe 
respiratory illness with a high fatality rate of 34.4%. At the end of November 2019, more than 
2,400 confirmed cases were reported, the majority in Saudi Arabia. This epidemic was marked 
by a high rate of nosocomial transmission with 19.1% of cases being healthcare workers (9).  
At the end of 2019, the first cases of SARS-CoV-2 were reported in Wuhan, a large city in 
Southern China, and were linked to the Huanan seafood market. Early Chinese data showed an 
exponential growth of the number of cases suggesting human-to-human transmission among 
close contacts (10). The World Health Organization (WHO) declared this outbreak a pandemic 
on March 11, 2020 and strict measures, such as social distancing and public health hygiene 
protocols, have been taken by many countries to limit the spread of the disease. In many 
countries, the pandemic is still in its exponential phase as of May 2020. 
SARS-CoV-2 causes an illness quite similar to the other emerging coronaviruses and was 
renamed “COVID-19” by the WHO on February 11, 2020. Typical symptoms of COVID-19 
pneumonia include fever, dry cough, anosmia and fatigue. These mild presentations represent 
This article is protected by copyright. All rights reserved.
  
81% of cases according to a large Chinese report of 72,134 cases (11), while 14% and 5% of 
cases present with severe or critical disease such as respiratory failure, septic shock, multip le 
organ dysfunction respectively. Similar data have been reported in the United States, with 
14.3% of patients requiring intensive care management and a mortality rate that has reached 
21% among hospitalized patients (12). The most frequent complications during hospitalizat ion 
are acute respiratory distress syndrome (ARDS), arrhythmia and shock, as well as 
thromboembolic diseases (13,14). Atypical SARS-CoV-2 symptoms, such as diarrhea and 
nausea, have been frequently reported (15) along with neurological symptoms and 
complications such as Guillain-Barré (16). In addition, there are increasing reports of 
asymptomatic infections (17)(18). This further complicates the calculation of exact mortality 
rates (19,20). In a recent model based analysis, the case fatality rate was estimated to be 0.32% 
[0.27–0.38%] in patients <60 years old (y.o.), 6.4% [5.7–7.2%] in older patients, reaching up 
to 13.4% (11.2–15.9%) in those > 80 y.o (21). Comorbid conditions, such as cardiovascula r 
disease, diabetes, chronic respiratory disease, hypertension, and cancer, have been shown to be 
associated with increased mortality (10.5% for cardiovascular disease, 7.3% for diabetes, 6.3% 
for chronic respiratory disease, 6.0% for hypertension and 5.6% for cancer) (11).  
 
IMPACT OF EMERGING CORONAVIRUSES IN PREGNANCY  
Current data regarding emerging coronaviruses and their impact in pregnancy are mostly based 
on case reports and small case series. As these are often biased by worse maternal and fetal 
outcomes, the subsequent section should be interpreted with caution.   
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Maternal outcomes 
Respiratory infections are known to be associated with an increased risk of maternal 
complications. This was observed during the Influenza A pandemic in 2009, where up to 23% 
of affected women required admission to intensive care and 8.2% of them died (3,22). The 
relative immunosuppressed state as well as the restricted respiratory capacity of pregnancy 
account for such outcomes (23). Current data regarding emerging coronaviruses, based mostly 
on case series, are summarized below.  
 
SARS-CoV-1. A total of 25 cases of SARS-CoV-1 infection among pregnant women were 
identified in the literature (24–30). Infections were observed in the first trimester (n=7), second 
trimester (n=4) and third trimester (n=14). Among the 25 cases of SARS-CoV, 3 maternal 
deaths (12%) were recorded, 10 patients required ICU admission (40%) with or without 
mechanical ventilation. Compared to non-pregnant women, the rates of ICU admission and 
maternal death were significantly higher and independent of the trimester of infection, includ ing 
2 patients in their first trimester. In one case, SARS-CoV-1 RNA was amplified within the 
cerebrospinal fluid and associated with seizures suggesting encephalitis (26).  
 
MERS-CoV. 12 cases of MERS-CoV infection among pregnant women were identified in the 
literature. Infections occurred in all trimesters of pregnancy (n=2 for 1st trimester, n=3 for 2nd 
trimester and n=6 for 3rd trimester). Three (40%) maternal deaths were identified, 7 (58.3%) 
required ICU admission and 2 (16.7%) patients remained asymptomatic. Complications were 
only observed among patients in their late 2nd or 3rd trimester. No severe adverse maternal 
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outcomes were observed among patients infected earlier in pregnancy. The fatality rate of 
MERS-CoV in pregnancy (36%) was similar to non-pregnant adults (35%) (31,32,34–38). 
 
SARS-CoV-2. As of April 22, 2020, more than 150 cases have been reported. We identified 
four cohort studies, including 118 (39) and 116 (40) Chinese patients, 42 Italian patients (41) 
and 43 American patients (42), respectively. Almost all infections occurred in the 3rd trimester 
or close to delivery. In general, pregnant women experienced symptoms similar to those of non-
pregnant patients, developing mild clinical symptoms in the majority of cases with mainly 
fever, cough and myalgia. Interestingly, among the American cohort, 32.2% (n=14/43) of 
patients were asymptomatic at the time of diagnosis. Six patients remained asymptomatic after 
positive testing, suggesting the possibility of completely asymptomatic disease, which supports 
the eventual need for routine screening (43).  
Severe cases of COVID-19 infection in pregnant women are not frequent as with the previous 
coronavirus infections described above. Nevertheless, nine (2.7%) maternal deaths have been 
reported among eleven Iranian patients with 3rd trimester infections (44–46). All women 
presented with typical symptoms, including dyspnea. They were previously healthy except two 
patients known for hypothyroidism and one patient with suspected gestational diabetes. 
Maternal age was between 22 and 49 y.o. and two women had dichorionic/diamniotic twin 
gestations. All women were admitted to the ICU, intubated and ventilated and died from 
cardiopulmonary collapse or multiple organ failure (MOF). One had septic shock and 
disseminated intravascular coagulation (DIC) before progressing to heart failure. Intrauter ine 
fetal death (IUFD) were described among four patients (4/9) with gestational ages between 24 
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and 30 WG. CS were performed in other cases (5/9) with gestational age between 30 and 38 
WG.    
Cohort studies have reported a rate of severe disease requiring ICU admission of 6.9-8% 
(n=9/118; n=8/116), including 3 requiring mechanical ventilation among Chinese patients. In 
the Italian cohort, a total of 17% of pregnant women (n=7/42) required either oxygen 
supplementation through continuous positive airway pressure (CPAP) or ICU admission, while 
in the American cohort, 4 (9.3%) presented with severe disease and 2 (4.7%) required ICU 
admission without mechanical ventilation.  
Severe complications in pregnant women are similar to what has been described in the general 
population and include multiple organ failure, respiratory failure requiring mechanica l 
ventilation, and even Extracorporeal Membrane Oxygenation, as described in a patient at 35 
WG (47). In the latter, the patient required an emergency cesarean section for maternal 
resuscitation and the newborn unfortunately died due to an intrauterine asphyxia. The mother 
had multiple organ failure, needed mechanical ventilation before Extracorporeal Membrane 
Oxygenation for a total of 7 days. She was discharged from hospital 6 weeks later. 
Two cases of cardiomyopathy related to COVID19 were reported by Juusela and al.(48). The 
first pregnant woman was 45 y.o., had a BMI of 44.6 m2/kg and was diagnosed with diet-
controlled gestational diabetes. She delivered via cesarean at 39 WG for severe preeclampsia 
and tested positive to SARS-CoV-2 on postpartum day 1 with evidence of fever, tachypnea and 
suspicious chest imaging. She was then diagnosed with acute heart failure after an 
echocardiogram was performed, showing a moderately reduced left ventricular ejection 
fraction (LVEF) of 40% with global hypokinesis. On day 5 postpartum, the mother required 
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mechanical ventilation and was still intubated at the time of publication. The second patient 
was a 26 y.o. women with no relevant medical history. She was admitted for respiratory 
symptoms necessitating nasal oxygen support. Due to the previous experience, an 
echocardiogram was completed and showed a moderately reduced LVEF of 40-45% with 
global hypokinesis. She rapidly developed severe features leading to a cesarean section at 34 
WG. At the time of publication, she was postpartum day 1 and did not require oxygen support.  
 
Though current data suggest that most pregnant women with COVID-19 will have an 
uncomplicated clinical course, severe complications must be anticipated. Nevertheless, the 
observed rates appear similar to those for non-pregnant patients between 20-40 years old. In a 
recent analysis based on a Chinese cohort, the actual rate of severe disease was 173/1170 (9.8%) 
among 20-39 y.o. patients; after adjusting for demographic factors, the expected rate of severe 
disease was 0.6-8.6% (21).  
Breslin et al. also reported a similar rate of complications in pregnant women compared to non-
pregnant adults (11): 86 vs 80 % with mild clinical symptoms, 9.3 vs 15 % with severe 
symptoms and 4.7 vs 5% requiring ICU admission respectively. We should point out, however, 
that complications in the general population mainly impacted the elderly and patients with 
comorbidities. When comparing pregnant woman to their typical age group, they qualify as a 
high-risk group for adverse maternal outcomes (49).  
Therefore, although the majority of infected pregnant women seems to demonstrate a mild 
clinical course, pregnancies should be approached with caution considering the potential critica l 
complications reported in several cases published so far report. More exhaustive data, however, 
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are needed to understand the additional risk pregnancy may pose to women with a COVID-19 
infection.  
 
Fetal and neonatal outcomes 
SARS-CoV-1 and MERS-CoV infections during pregnancy were associated with adverse fetal 
and neonatal outcomes.  
 
SARS-CoV-1. A report on twelve pregnant women suffering from SARS-CoV-1 (2002-03 
pandemic) was published (50) and the rate of adverse fetal / neonatal outcomes was 66% (8/12) 
in this series. Four of the seven patients (57%) infected during the first trimester experienced 
miscarriages. Two others decided to terminate their pregnancy after recovering from SARS, 
and the last had an uncomplicated pregnancy. Among the five patients infected during the 
second or third trimester, four (4/5, 80%) had a preterm delivery, including one for fetal distress 
(1/5, 20%). Two neonates exhibited respiratory distress syndrome and other complications 
related to prematurity (necrotizing enterocolitis). All placentas of these patients (5/5, 100%) 
weighed below the 5th percentile, of which 2 had abnormal anatomo-pathology results 
(thrombotic vasculopathy with avascular fibrotic villi and / or placental infarct) (51). When the 
infection occurred during the week before birth, no fetal growth restriction was noted (0/2). 
When the infection occurred one month or more before birth, two fetuses (2/3, 33%) had fetal 
growth restriction (FGR) with oligohydramnios, related to the abnormal placentas presented 
above. Another Chinese series (52) reported fetal demise in one of five (20%) fetuses exposed 
to SARS-COV-1 during the second or third trimester of pregnancy.  
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MERS-CoV. Eleven fetuses / neonates from mothers infected with MERS-CoV have been 
described (53)(54)(55). Among them, 3 (3/11, 27%) had fetal or neonatal demise: two intra-
uterine fetal deaths at 20 and 34 weeks, and one neonatal demise at 24 weeks due to extreme 
prematurity (55)(56). Abruption was identified on placental examination from these fetuses, 
and from another liveborn neonate who presented with fetal distress at 37 weeks (57).   
 
SARS-CoV-2. With regards to SARS-CoV-2 infection during pregnancy, several case-series 
and case reports show that similar adverse fetal and neonatal outcomes could occur. Overall, 
we included 142 cases with fetal and/or neonatal outcomes available at the time of this review. 
Among them, 40 (28%) were born prematurely (<37w) and 20 (14%) had adverse outcomes 
(FGR, fetal or neonatal demise, severe symptoms at birth). Congenital or perinatal transmiss io n 
was suspected in 6 of 115 (5%) newborns tested. Details of all cases available are presented in 
Table 1.  
In a case-control study (58), among 17 fetuses from SARS-CoV-2 infected mothers, 3 exhibited 
FGR (3/17, 18%), 2 had fetal distress (2/17, 12%), and four were born prematurely (4/17, 24%) 
due to PROM or placental bleeding. The rates of low birth weight and premature birth were 
significantly higher when compared to the control groups. One of these fetuses also exhibited 
sinus tachycardia that persisted after birth. Zhu and colleagues (59) described the outcomes of 
10 neonates from SARS-CoV-2 infected mothers. Two of them were small for gestational age 
(2/10, 20%), and 6 had a Pediatric Critical Illness Score (PCIS) below 90 with shortness of 
breath (6/10, 60%), fever (2/10, 20%), thrombocytopenia accompanied by abnormal liver 
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function (2/10, 20%), tachycardia (1/10, 10%), vomiting (1/10, 10%), and pneumothorax (1/10, 
10%). Neonatal radiography showed abnormalities in 7 of them (7/10, 70%): 4 had signs of 
infection, 2 respiratory distress syndrome and 1 pneumothorax. Among these neonates, two 
(2/10, 20%) had disseminated intravascular coagulation and one (1/10, 10%) refractory shock 
with multiple organ failure leading to death at day 8 of life. Liu Y. (60) presented the outcomes 
of 10 other newborns exposed during pregnancy: none which were positive for SARS-CoV-2 
at birth, 6 (6/10, 60%) were premature (for fetal distress in 3 cases, 3/10, 30%), and one was 
stillborn (1/10, 10%). Chen and colleagues (61) described a series of 9 newborns from infected 
mothers during the third trimester. Two (2/9, 22%) had a low birthweight and four (4/9, 44%) 
were premature (for fetal distress in 2 cases), none experienced a severe adverse outcome. Yu 
and colleagues also reported a series of 7 newborns from infected mothers during the third 
trimester, without adverse outcomes. One of these neonates had a positive SARS-CoV-2 PCR 
36 hours after birth, leading to the suspicion of a perinatal transmission.  Liu D. and colleagues 
(62) described briefly the outcomes of 13 newborns from infected mothers. Induced prematurity 
was noted in 54% (7/13), but none had neonatal complications. In the New-York series (42), 
which presented the outcomes of 18 infants from infected mothers, all but one had negative 
neonatal testing for SARS-CoV-2. One infant had an ‘indeterminate’ test result, which was 
clinically managed as a ‘presumptive negative’ diagnosis, as this result may reflect low level 
detection. In this series, 3 (3/18, 17%) instances of fetal distresses were noticed, one infant 
(1/18, 6%) was premature and one (1/18, 6%) presented with RDS with a concern for sepsis. 
Zeng and colleagues (63) reported the largest series to date, with 33 newborns included. A 
perinatal infection was suspected in three of them (3/33, 9%), with a positive PCR at day 2 and 
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4 of life. Infected newborns presented with higher rates of FGR, prematurity and complications 
at birth (fever, pneumonia, RDS, shortness of breath) than non-infected newborns: 33% vs 7%, 
33% vs 10 %, 100% vs 10%, respectively. Wang (64) reported one case with a positive PCR in 
both the mother and her newborn (whereas placental and umbilical blood samples were 
negative). This newborn had lymphocytopenia, abnormal liver function and elevated creatine 
kinase, although was clinically stable. Congenital or perinatal transmission was also suspected 
in three other cases (65)(66). SARS-CoV-2 IgM antibodies were elevated in these three 
newborns, although their nasopharyngeal PCRs were negative. In an editorial related to these 
cases, Kimberlin (67) pointed out that false-positive results due to cross-reactivity of IgM could 
occur and perinatal testing remains a challenge.  
Interestingly, Zamaniyan and al.(68), described a case of positive SARS-CoV-2 amniot ic 
sample from a newborn, raising concern about potential vertical transmission in mothers with 
serious illness. Indeed, possible vertical transmission has been questioned by other authors 
(65,66) and remain unclear.  
 
A case of second trimester miscarriage was reported by Baud and al.(69) in a patient at 19 WG 
positive for SARS-CoV-2. Virological findings confirmed the presence of the virus in the 
placenta, but not in fetal tissue or maternal samples, suggesting a potential impact of SARS-
CoV-2 early in the pregnancy.  
In other CoV infections during the second or third trimester of pregnancy, it is interesting to 
note that placental changes seem to precede FGR. Severe maternal respiratory illness related to 
CoV infection may lead to a circulatory insufficiency in both the placenta and the fetus. Thus, 
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a maternal COVID infection could affect the oxygen supply, leading to placental insufficiency, 
IUGR, fetal distress and / or fetal demise. A direct impact of the virus itself, by increasing fibrin 
deposits or thrombo-embolic events in the placenta, cannot be excluded and warrants further 
investigation. 
Similarly, maternal SARS related to CoV-2 infection during the first trimester of pregnancy 
could disrupt the uterine placental flow, leading to miscarriage. Although the risk of miscarriage 
has been described with SARS-CoV-1 infection, no cases have yet been reported with SARS-
CoV-2 infection. 
 
MANAGEMENT OF PREGNANT WOMEN WITH A SEVERE ACUTE 
RESPIRATORY DISEASE 
Currently, no curative agent has been found for COVID-19. Studies conducted so far (includ ing 
randomized controlled trials = RCTs) have been plagued by poor methods and reporting, such 
as exclusion of patients with worse outcome from the treated group, different endpoints 
between protocols and published reports, premature stopping of RCT (leading to lack of 
statistical power), use of endpoints of no clinical value (such as viral load), degrees of severity 
of enrolled patients (so that the benefit of a treatment or lack thereof in a cohort of patients may 
not generalizable to patients with different degrees of severity, lack of optimization of treatment 
dose or duration of treatment, to name but a few). 
 
Pharmacological options for SARS-CoV-2 in pregnancy 
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Several drugs are currently being evaluated as potential treatment for SARS-CoV-2 includ ing 
hydroxychloroquine, lopinavir-ritonavir combination, remdesivir, oseltamivir, Interferon 
alpha, darunavir, baricitinib, tocilizumab and immunoglobulin therapy.  
Hydroxychloroquine use in pregnant women has raised concerns in the past especially for an 
increased risk of cardiac malformation (70) and its retinal and ototoxicity (71)(72), related to 
the use of chloroquine and not hydroxychloroquine, findings which were not confirmed in more 
recent case series (73)(74)(75)(76). In the most recent systematic review and meta-analys is 
conducted in 2016, Kaplan YC et al (77), found no increase “in the rates of major congenita l 
craniofacial and cardiovascular, nervous system and genitourinary malformations in the 
infants.” However, there was a significant increase in the spontaneous abortion rate, which 
could be associated with the underlying disease activity rather than the treatment. That being 
said, (hydroxy)chloroquine is one of the antimalarial drugs considered compatible with 
pregnancy in all trimesters for prophylaxis and treatment of malaria (78,79). A recent article 
gathered evidence on its use during lactation and found that it was compatible with 
breastfeeding (80), concluding that hydroxychloroquine could be used for the treatment of 
COVID-19 infection, in usual rheumatological doses (200-400 mg/day) if proven to be 
effective.  
The lopinavir ritonavir combination is used as part of the HAART regimen to treat HIV infected 
women during pregnancy (81). In a systematic review that included 4,864 LPV/r-exposed 
pregnancies, the authors reported the rate of congenital abnormalities to be similar to that of the 
general population. However, the stillbirth rate was higher than in the general population in the 
UK (9.2 per 1000 infants against 4.7 per 1000 infants in 2013) (82). There has been general 
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concern regarding protease inhibitor exposure in utero and its association with an increased risk 
of preterm birth (83), however, to our knowledge this risk has not been evaluated specifica lly 
for lopinavir and ritonavir alone, and could be associated with the underlying disease activity 
rather than the treatment. Finally, moderate adverse events such as gastro-intestinal symptoms 
(84) and an increased risk for alteration in fasting glycemia (85) were reported. Lopinavir and 
ritonavir are drugs considered compatible with pregnancy in all trimesters for HIV treatment 
and has been associated with very low excretion into breastmilk (78,79).  
Regarding remdesivir, no adverse effect was reported in pregnant participants in a randomized 
controlled trial on Ebola virus (86). Safety data on remdesivir in pregnancy are still scarce. 
Oseltamivir was used during the 2009 influenza A/H1N1 pandemic and notably in pregnant 
mothers. In the most recent population-based study (87) conducted on 946,176 pregnancies in 
Denmark from 2002 to 2013 of which 1898 were exposed to oseltamivir during pregnancy, 
Ehrenstein.V and colleagues found no increased risk of any major congenital malformatio n, 
fetal death, preterm birth, SGA or low 5-min APGAR score. This confirmed previous 
observations from the European registry study (88) and the Roche Global Safety Database (89). 
Oseltamivir could be considered compatible with pregnancy in all trimesters if proven effective 
in COVID-19 treatment and has been associated with very low excretion into breastmilk 
(78,79). 
 
The Interferon alpha drug (INFα) is used to treat essential thrombocythemia, chronic 
myelocytic leukemia or hepatitis B and C in pregnant women. In a recent review including 43 
exposed women, Sakai K et al. found that no adverse event had required discontinuation of the 
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treatment but alerted physicians to “pay attention to (…) rare adverse events, such as impaired 
liver function, interstitial pneumonia, and attempts at suicide” (90). Safety data on INFα in 
pregnancy are scarce but its similarity to beta interferon, of which safety data during pregnancy 
are substantial and reassuring, makes it compatible in pregnancy if proven effective for 
COVID-19 infection. 
Regarding darunavir, no embryotoxicity or teratogenicity of this molecule was found in anima l 
studies (91). In a brief review of darunavir use in pregnant women, the authors concluded that 
it is a well-tolerated molecule which has few minor adverse effects (92). Darunavir is 
considered compatible with pregnancy in all trimesters for HIV treatment despite its lack of 
safety data in pregnancy as its maternal benefit outweighs the potential unknown risks (78,79). 
Animal studies have demonstrated embryotoxicity of baricitinib (93) and no safety data are 
available in human. 
Analysis of the Roche Global Safety Database does not suggest a substantially increased risk 
of malformations with the use of Tocilizumab. However, an increased rate of preterm birth and 
low birth weight children was possibly associated with TCZ exposure and could be associated 
with the underlying disease activity rather than the treatment (94). Safety data in pregnancy are 
limited and due to treatment- induced immunosuppression, an increased risk of maternal- feta l 
infections is theoretically possible in pregnant women treated with tocilizumab. 
Finally, serum from convalescent COVID-19 patients and hyperimmune globulins specific to 
the novel coronavirus are currently being evaluated as therapeutic options (95). 
Specific hyperimmune globulins have been used in several indications during pregnancy, 
including prevention of mother to child transmission of infectious diseases such as Hepatitis B 
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virus (HBV) (96) and Cytomegalovirus (CMV) (97), as well as convalescent serum recently in 
the Ebola virus disease (EBV) (98). 
In a systematic review assessing the benefits and safety of hyperimmune globulins to prevent 
HBV mother to child transmission in 2440 pregnant women, only one study mentioned adverse 
events consisting in swelling in two women (96). More recently, convalescent serum to treat 
the Ebola virus disease was evaluated in a non randomized comparative study of 99 patients 
which included eight pregnant women. No serious adverse reaction were associated with the 
transfusion (98). 
Two cases of pregnant women report the use of convalescent serum to treat SARS-CoV-2 
infection (47,99). In the first case of a 31 years old pregnant woman, no serious adverse event 
related to the use of convalescent plasma was reported but its relative contribution to surviva l 
could not be determined due to other concomitant treatments. The authors concluded that its 
clinical benefit remained unknown (47). In the second case of a 35 year old pregnant woman 
with severe co morbidities who received both convalescent serum and remdesivir, no 
conclusion regarding safety or benefit of convalescent plasma could be drawn by the authors 
(99).              
Data on the use of specific hyper immunoglobulins to prevent infections in pregnant women 
seem reassuring as well as those on the use of convalescent serum although they are more 
scarce.  If they proved to be effective in COVID-19 treatment,  convalescent serum and specific 
hyper immunoglobulins directed against SARS-CoV-2 could be considered compatible with 
pregnancy in all trimesters.   
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Prenatal monitoring (Table 2) 
Regarding potential asymptomatic infected pregnant women, the WHO recommends careful 
monitoring of patients with epidemiological history of contact with infected individuals, while 
The American College of Obstetricians and Gynecologists (ACOG) suggests routine antenatal 
care in this situation. An algorithm for assessment and management of symptomatic parturients 
has been proposed by ACOG, classifying them in three categories of risk: low, moderate and 
elevated. For mild presentations, women without comorbidities (low risk) should self-isolate at 
home, whereas those with health problems, obstetrical issues or the inability to care for 
themselves (moderate risk) should be seen in an ambulatory setting. According to The Royal 
College of Obstetricians and Gynaecologists (RCOG), pregnant women with moderate 
symptoms should self-isolate, unless they attend a maternity unit where patients in the 2nd or 
3rd trimester meeting PHE criteria ( ≥ 1 of: (1) Clinical/radiological evidence of pneumonia, (2) 
Acute Respiratory Distress Syndrome (ARDS), (3) Fever ≥37.8 and at least one of acute 
persistent cough, hoarseness, nasal discharge/congestion, shortness of breath, sore throat, 
wheezing or sneezing) should be tested for COVID-19 and treated as infected until results are 
available. When pregnant women present with severe symptoms (high risk), they should 
immediately go to an emergency department according to ACOG algorithm. All guidelines 
agree that administration of corticosteroids for fetal lung maturity is still recommended per 
protocol for in the setting of a high risk of preterm birth when the mother’s condition is stable.  
Regarding fetal growth surveillance, RCOG recommends an antenatal ultrasound fourteen days 
after acute illness resolution for hospitalized patients, while ACOG suggests a 3rd trimester 
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ultrasound for COVID-19 pregnant women infected in 2nd and 3rd trimester. A detailed anatomy 
ultrasound could be considered for 1st trimester infections (ACOG).  
 
Risk of thromboemboloic disease  
Data suggest that COVID-19 may be associated with an increased thromboembolic risk with a 
rate of venous thromboembolism (VTE) of 39% in ICU patients (100). Therefore, routine VTE 
prophylaxis for hospitalized COVID-19 patients is recommended by the American Society of 
Hematology, the Society of Critical Care Medicine, and the International Society of 
Thrombosis and Haemostasis (101–103), in absence of contraindications. The decision between 
LMWH or unfractionated heparin (UFH) should be discussed with consideration for the risks 
and benefits. RCOG advises measures such as hydration and mobility for pregnant women 
isolated at home who are not taking thromboprophylaxis. If a woman has risk factors for VTE, 
a clinical review should be attempted and VTE risk assessed to consider the introduction of 
prophylactic treatment with LMWH at home. Routine thromboprophylaxis for hospitalized 
parturients with LMWH is suggested unless birth is expected within 12 hours. In the postpartum 
period, VTE risk should be assessed and the first dose of LMWH should be administrated as 
soon as possible after birth. At the time of discharge from hospital, all women (antepartum or 
postpartum) should be prescribed at least 10 days of LMWH, according to RCOG 
recommendations. For management of critical illness, the WHO recommends the use of 
LMWH to reduce the incidence of VTE.  
Use of prophylactic aspirin for the prevention of preeclampsia and other indications, such as 
antiphospholipid syndrome (APS) or prevention of fetal growth restriction, is controversial in 
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the context of COVID-19 infected women (104). Use of non-steroid anti-inflammatory drugs 
(NSAIDs) can worse pulmonary disease and symptomatic COVID-19 non-pregnant patients 
treated with ibuprofen have experienced disease progression (105,106). However, ongoing 
RCT are evaluating the early use of aspirin in covid-19 patients, which has the effects of 
inhibiting virus replication, anti-platelet aggregation, anti-inflammatory and anti-lung injury 
(107). For pregnant women, ACOG suggests decision on low-dose aspirin treatment should be 
taken individually. According to Kwiatkowski and al.(108), benefits of placental complications 
prevention outweigh the potential risks of adverse outcomes of SARS-CoV-2 infection related 




For the first time in a century, we are facing a SARS-coronavirus global pandemic and we have 
to deal with numerous new challenges in terms of public health service. The global impact on 
pregnant women can only be hypothesized from recent observations gathered during the past 
few months from different parts of the world.  
Other coronavirus epidemics, such as SARS-CoV-1 had a higher impact on pregnant women 
encompassing 40% of ICU admissions and 12% of mortalities. The MERS-CoV epidemic was 
even more lethal with a 40% mortality without significant difference of severity between 
pregnant and non-pregnant women.  In this review, we gathered more than 150 cases of SARS-
CoV-2 in pregnancy and identified a maternal mortality of 2.7% (9 cases) among those 
described in the literature. ICU admissions were between 6.9% and 8%. The proportion of 
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severe complications seem to be equal to the non-pregnant population, however these must still 
be anticipated in pregnant women. These rates will have to be reviewed when the true 
denominator (number of infected pregnant women) is known, as a significant proportion of 
patients remain asymptomatic. 
Past coronavirus epidemics were associated with adverse outcomes for the fetus and/or 
newborns including miscarriages (57%), preterm birth, fetal distress and FGR with SARS-
CoV-1 infection during the 2nd and 3rd trimesters. Also, MERS-CoV infection resulted in fetal 
and neonatal demise in 27% of cases. In this review, we found that of 142 cases of SARS-CoV-
2 infections in pregnancy, 28% experienced preterm birth and 14% had adverse fetal/neonata l 
outcomes (FGR, fetal/neonatal demise, severe symptoms at birth). Potential mechanisms 
include placental changes, as observed with SARS-CoV-1, and severe respiratory maternal 
illness, which could lead to placental insufficiency, IUGR and fetal distress/demise. The role 
of SARS-CoV-2 in early adverse pregnancy outcomes needs further investigation. 
With regards to pharmacological management, most agents currently tried are safe in 
pregnancy. 
As of April 22, 2020, prenatal management should be adapted to the patient’s condition as 
indicated by ACOG and other algorithms (109). There is currently no agreement on specific 
prenatal ultrasound surveillance, but due to the potential risk of IUGR, it would seem 
reasonable to assess fetal growth surveillance during the third trimester of pregnancy. 
Administration of corticosteroids in pregnant women at risk of preterm birth should be 
administered per protocol, with consideration for the patient’s condition. We recommend 
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considering parental preferences, the severity of illness and obstetrical indications when 
addressing the mode of delivery.  
Guidelines for pregnancy management will continue to be updated and professionals should 
stay informed about new guidelines.  
 
CONCLUSIONS AND FUTURE WORK 
The acquisition of robust data on the impact of emergent pathogens on pregnant women is often 
lacking or only available after a considerable delay (4) leaving scientists and clinicians to 
develop knowledge from intuition, extrapolation and case series as they emerge.  Adaptive 
systems enabling prospective and structured collection of information on pregnant women 
during epidemics are needed. They allow for faster knowledge acquisition, through specific 
epidemiological studies based on robust data, and tailoring of preventive and screening 
strategies to improve maternal, fetal and neonatal outcomes in a timely manner. Recruitment of 
pregnant women with COVID-19 in cohort studies should be encouraged globally to allow for 
evidence-based management. Currently, several registries are open for recruitment. COVI-Preg 
is an international hospital-based registry enrolling pregnant women at any stage of pregnancy 
with a suspected SARS-CoV-2 infection (110). PRIORITY (Pregnancy CoRonavIrus 
Outcomes RegIsTrY) is a US nationwide study of pregnant or postpartum women who are 
either under investigation for Coronavirus infection (COVID-19) or have been confirmed to 
have COVID-19 (111). CHOPAN (Coronavirus Health Outcomes in Pregnancy and Neonates) 
is a hospital-based registry aiming to collect real-time data on pregnant women who are infected 
with SARS-CoV2 in Australia, New Zealand & the Pacific region (112). International Registry 
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of Coronavirus (COVID-19) Exposure in Pregnancy (IRCEP) is a patient-based registry 
enrolling any women who are currently pregnant or have been pregnant within the last 6 
months, and who have been tested for SARS-CoV-2 (regardless of the result) or have been 
clinically diagnosed with COVID-19 by a health care professional (113). 
These initiatives should provide several datasets available for research aiming to improve 
pregnant patient care during the COVID-19 pandemic in the near future.  
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Table 1: Fetal and neonatal outcomes after coronavirus infection during pregnancy
MERS-CoV SARS-CoV 1 SARS-CoV 2
Alfaraj, 2019 Wong, 2004 Zhang, 2003 TOTAL Zhu, 2020 Li, 2020 Breslin, 2020 Yu, 2020 Liu D., 2020 Chen, 2020 Zeng, 2020 Liu Y., 2020 Zhang, 2020 Yin, 2020 Yang, 2020 Case reports TOTAL
1st Trimester infection n=1 n=7 n=0 n= 7 n=0 n=0 n=0 n=0 n=0 n=0 n=0 n=0 n=0 n=4 n=0 n=0 n=4
- TOP 2 (29%) 2 (29%) 3 (75%) 3 (75%)
- miscarriages 0 (0%) 4 (57%) 4 (57%) 0 (0%) 0 (0%)
2nd and 3rd Trimester infection n=10 n=5 n=5 n=10 n=10 n=17 n=18 n=7 n=13 n=9 n=33 n=10 n=16 n=17 n=13 n=11 n= 174
- FGR * 2 (40%) * 2/5 * (40%) 2 (20%) 3 (18%) * 0 (0%) * 2 (22%) 3 (9%) * * 1 (6%) * 1 (9%) 12/102 * (12%)
- fetal distress * 1 (20%) * 1/5 * (20%) 6 (60%) 2 (12%) 3 (17%) * * 2 (22%) * 3 (3%) 1 (6%) 1 (6%) * 3 (27%) 21/141 * (15%)
- fetal demise 2 (20%) 0 (0%) 1 (20%) 1/10 (10%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (10%) 0 (0%) 0 (0%) 0 (0%) 1 (9%) 1/174 (1%)
- preterm birth < 37w 5 (50%) 2 (40%) * 2/5 * (40%) 6 (60%) 4 (24%) 1 (6%) 0 (0%) 7 (54%) 4 (44%) 4 (12%) 6 (60%) 3 (19%) 5 (29%) 2 (15%) 7 (64%) 49/174 (28%)
- neonatal demise 1 (10%) 0 (0%) * 0/5 * (0%) 1 (10%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (9%) 2/173 (1%)
- RDS at birth * 2 (40%) * 2/5 * (40%) 6 (60%) 0 (0%) 1 (6%) 0 (0%) 0 (0%) 0 (0%) 4 (12%) 0 (0%) 1 (6%) 0 (0%) 3 (23%) 2 (18%) 14/173 (8%)
- other complications * 2 (40%) * 2/5 * (40%) 6 (60%) 1 (6%) 0 (0%) 0 (0%) * 0 (0%) 4 (12%) 0 (0%) 1 (6%) 0 (0%) * 4 (36%) 16/147 * (11%)




Case-reports of SARS-CoV2 infections during pregnancy includes: (16–21)
Abbreviations: FGR, Fetal growth restriction; RDS, respiratory distress syndrome
* missing data in the description of fetal / neonatal outcomes
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 • Fever ≥37.8 AND at least one of acute persistent cough, hoarseness, nasal discharge/congestion, 
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6 ACOG algorithm available at : https://www.acog.org/clinical/clinical-guidance/practice-
advisory/articles/2020/03/novel-coronavirus-2019 
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Annexe 1. Publications for: “(COVID-19 OR SARS-Cov2 OR coronavirus) and (pregnancy OR pregnant)” research on PubMed on 22 
April 2020. 
 
 Author / Title Type of 
research 
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patients 
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mother to child: A 
case report 
Case report Journal of 
infection and 
Public Health 
1 The nucleic acid test from the mother's amniotic fluid, vaginal 
secretions, cord blood, placenta, serum, anal swab, and breast 
milk were also negative. The most comprehensively tested 
case reported to date confirmed that the vertical transmission 
of COVID is unlikely. 






Case report American 
journal of 
perinatology 
1 The patient developed respiratory failure requiring 
mechanical ventilation on day 5 of disease onset. The patient 
underwent a cesarean delivery, and neonatal isolation was 
implemented immediately after birth, without delayed cord 
clamping or skin-to-skin contact. The neonatal 
nasopharyngeal swab, 16 hours after delivery, was positive 
for severe acute respiratory syndrome–coronavirus 2 (SARS-
CoV-2). 







first 4 weeks in New 
York. 




21’980 We used data that were concurrently collected at a large 
hospital 30 group in New York State between March 2 and 
March 29, 2020. Routine SARS31 CoV-2 testing was not 
performed. Data included the week of admission, the 32 
pregnancy status of the patient, and the SARS-CoV-2 status 
(positive or negative).  










4 Kwiatkowski S,  
Why we should not 
stop giving aspirin 
to pregnant women 
during the COVID-
19 pandemic. 
Review Ultrasound in 
Obstetrics & 
Gynecology 
none To our knowledge, there is insufficient data to suggest an 
increased risk between prophylactic use of low‐dose aspirin 
and progression of COVID‐19 infection in pregnant women 
at risk of placental complications. 
5 Jamieson DJ, 




Lines and the 
Confusing World of 
Personal Protective 
Equipment. 
Review Obstetrics & 
Gynecology 
none Therefore, strict adherence to hand hygiene and consistent 
use of recommended personal protective equipment are 
cornerstones for reducing transmission. In addition, it is 
critical that health care professionals receive training on and 
practice correct donning (putting on) and doffing (removing) 
of personal protective equipment 
6 Zamaniyan M,  







Case report Prenatal 
Diagnosis 
1 In this present study, we presented a pregnant woman with 
severe COVID-19 pneumonia who delivered a healthy 
preterm baby with no evidence of COVID-19 in her 32 weeks 
of gestation. Her RT-PCR test for COVID-19 was positive 
for amniotic fluid sample and second neonate nasal and throat 
test, but negative for vaginal secretion or umbilical cord 
blood or first neonate test.  








none This review will discuss what is known about the virus as it 
relates to pregnancy and then consider management 
considerations based on these data. 










8 Yang P,  
Clinical 
characteristics and 
risk assessment of 
newborns born to 
mothers with 
COVID-19. 





The current data show that the infection of SARS-CoV-2 in 
late pregnant women does not cause adverse outcomes in 
their newborns, however, it is necessary to separate newborns 
from mothers immediately to avoid the potential threats. 
9 Vlachodimitropoul




Review Journal of 
thrombosis and 
haemostasis 
none The laboratory derangements may be reminiscent of HELLP 
syndrome, and thus knowledge of the COVID19 relationship 
is paramount for appropriate diagnosis and management. In 
addition to routine measurements of D-dimers, prothrombin 
time, and platelet count in all patients presenting with 
COVID19 as per ISTH guidance, monitoring of APTT and 
fibrinogen levels should be considered in pregnancy, as 
highlighted in this report. 
10 Li L,  









none We thank Moradi et al. [1] for their interest in our article 
“Pregnancy and Perinatal Outcomes of Women with 
Coronavirus Disease (COVID-19) Pneumonia: A Preliminary 
Analysis” [2] and their efforts to point out the error in Table 3. 
After consideration of the information presented by Moradi et 
al., we have corrected the contents of Table 3 




with Covid-19 in 
Wuhan, China. 




118 We extracted information regarding epidemiologic, clinical, 
laboratory, and radiologic characteristics, treatment, and 
outcomes of pregnant women with Covid-19 through the 
epidemic reporting system of the National Health 
Commission of China, which stores the medical records of all 
50 designated hospitals in Wuhan city. 
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51 Although vertical transmission of SARS-Cov2 has been 
excluded thus far and the outcome for mothers and fetuses 
has been generally good, the high rate of preterm cesarean 
delivery is a reason for concern. These interventions were 
typically elective, and it is reasonable to question whether 
they were warranted or not. 
13 Monteleone PA,  
A review of initial 







Review JBRA assisted 
reproduction 
none Reported data suggest that symptoms in pregnant women are 
similar to those in other people, and that there is no evidence 
for higher maternal or fetal risks 
14 Li L,  
Follow-Up 
Information About 





Who Were Still in 
the Hospital at the 
End of Our Study. 
Case report American 
journal of 
roentgenology 
4 Our observations in our article and this letter provide a basis 
for guidelines on monitoring and treatment of oregnant women 
with confirmed COVID-19 pneumonia. Our findings indicate 
that treatment of pregnant women with antiviral drugs, which 
are associated with potential risks to the fetus, may not be a 
prerequisite for recovery from COVID-19 pneumonia.  





















none In this Viewpoint, we call attention to the need and urgency to 
engage pregnant women in COVID-19 treatment trials now in 
order to develop data-driven recommendations regarding the 
risks and benefits of therapies in this unique but not 
uncommon population. 
16 Yang H,  
Clinical Features 





Case report Journal of 
infection 
55 The clinical symptoms and laboratory indicators are not 
obvious for asymptomatic and mild COVID-19 pregnant 
women. Pulmonary CT scan plus blood routine examination 
are more suitable for finding pregnancy women with 
asymptomatic or mild COVID-19 infection, and can be used 
screening COVID-19 pregnant women in the outbreak area of 
COVID-19 infection. 






Two weeks of 
confirmed 
presentations to an 
affiliated pair of 
New York City 
hospitals. 





43 We now describe a series of 43 test-confirmed cases of 
COVID-19 presenting to a pair of affiliated New York City 
hospitals over two weeks from March 13 to 27, 2020.  















COVID 1 -19) 











79 In mothers infected with coronavirus infections, 
including COVID-19, >90% of whom also had pneumonia, 
PTB is the most common adverse pregnancy outcome. 
Miscarriage, preeclampsia, cesarean, and perinatal death (7-
11%) were also more common than in the general population. 
There have been no published cases of clinical evidence of 
vertical transmission 






Review Drugs & 
therapy 
perspectives 
none This commentary reviews the available information on 
managing COVID-19 during pregnancy to preserve the health 
of mothers and children in this critical situation. 
20 Mayor S,  
Covid-19: Nine in 
10 pregnant women 




small study finds. 
Comment The BMJ none Nearly 90% of pregnant women admitted to hospital for 
delivery who test positive for SARS-CoV-2 have no symptoms 
of the infection, a small study has found 
21 Moradi B,  








none It seems that the data in the second and third columns in Table 
3 have been transposed, which needs correction.  










22 Joseph Davey D, 
Contracting HIV or 
Contracting SAR-
CoV-2 (COVID- 
19) in Pregnancy? 
Balancing the Risks 
and Benefits. 
Notes AIDS and 
behavior 
none Given the evidence and our experience, we argue that the 
benefits outweighs the risks in pregnant women and advocate 
for continued PrEP provision and HIV risk reduction 
counselling in HIV-uninfected pregnant and breastfeeding 
women at high-risk of HIV acquisition in South Africa. 
23 Karami P,  
Mortality of a 
pregnant patient 
diagnosed with 
COVID-19: A case 








1 This report highlights details on a pregnant case of COVID-19 
who unfortunately did not survive. This 27-year-old woman at 
her 30 and 3/7 weeks’ gestation was referred to our center with 
fever, myalgia, and cough. The laboratory investigations 
showed leukopenia and lymphopenia as well as increased 
creatinine and CRP levels. 
24 Ashokka B,  
Care of the 
Pregnant Woman 
with COVID-19 in 





diagnosis in the 
acutely ill 
parturient, Care of 
the newborn, and 








none We present here the best evidence available to  address many 
of these challenges, from making the diagnosis in symptomatic 
cases, to the debate between nucleic acid testing and chest 
imaging, to the management of the unwell patient in labor. 
 










25 Khan S,  
Impact of COVID-
19 infection on 
pregnancy 











3 We report a case report study of 3 pregnant women with 
laboratory-confirmed COVID-19 pneumonia. All 3 pregnant 
women had vaginal deliveries. These patients presented with 
symptoms manifested by people with COVID-19.2 Of 3 
patients, only 1 patient delivered a preterm baby. 













none In conclusion, strict monitoring of women with suspected 
2019-nCoV is firmly recommended. Obstetricians should 
promptly recognize the symptoms of 2019-nCoV, and 
















none With interest, we read the guidelines by Guillaume Favre and 
colleagues1 on the management of pregnant women with 
suspected severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) infection. Therefore, we propose a translated 
algorithm for Spanish-speaking countries (appendix). We also 
suggest that the new breastfeeding recommendations and the 
option to use dexamethasone as an alternative to 
betamethasone are adopted in Latin America. 
 

















and general women. 
Case series Clinical 
microbiology 
and infection 
17 In summary, we found two neonates suspected for 
COVID-19 infection and five neonates with neonatal 
pneumonia, suggesting the possibility that adverse pregnancy 
outcomes may be linked to COVID-19 infection. 
29 Shah PS,  
Classification 











none At present the evidence for intrauterine transmission from 
mother to fetus or intrapartum transmission from mother to the 
neonate is sparse. There are limitations associated with 
sensitivity and specificity of diagnostic tests used and 
classification of patients based on test results has also been 
questioned. 
30 Deprest J,  
Feto-placental 






none Fetal diagnosis and pregnancy care need to be maintained, 
and we should strive to preotect the vulnerable population of 
pregnant women as well as their fetus, as much as possible. 
This includes both SARS-CoV2-negative and positive 
patients with fetal anomalies that may benefit from prenatal 
intervention.  
31 Mimouni F,  






Review Journal of 
Perinatalogy 
none Vertical transmission from maternal infection during the third 
trimester probably does not occur or likely it occurs very 
rarely. Consequences of COVID-19 infection among women 
during early pregnancy remain unknown. We cannot conclude 
if pregnancy is a risk factor for more severe disease in women 
with COVID-19. Little is known about disease severity in 
neonates, and from very few samples, the presence of SARS-
CoV-2 has not been documented in human milk. 










32 Wilson AN,  
Caring for the 
carers: Ensuring the 
provision of quality 
maternity care 
during a global 
pandemic. 
Review Women and 
birth 
none This article provides an overview of important considerations 
for supporting the emotional, mental and physical health needs 
of maternity care providers in the context of the unprecedented 
crisis that COVID-19 presents. Cooperation, planning ahead 
and adequate availability of PPE is critical. Thinking about the 
needs of maternity providers to prevent stress and burnout is 
essential. 










none We recommend that labor and delivery personnel have the 
utmost caution and be granted the protection they need to 
protect themselves and other patients. This includes providing 
labor and delivery personnel full PPE including N95 for the 
second stage of labor. This is critical to ensure the adequate 
protection for health care workers and to prevent spread to 
other health care workers and patients. 
34 Xiong X,  
Vaginal Delivery 
Report of a Healthy 




Case report Journal of 
medical 
virology 
1 We report a case of a convalescing pregnant woman diagnosed 
as COVID‐19 infection 37 days before delivery in the third 
trimester. A live birth without SARS‐CoV‐2 infection was 
delivered successfully via the vagina. Findings from our case 
indicate that there is no intrauterine transmission in this 
woman who develops COVID‐19 pneumonia in late 
pregnancy. 































ie : AINS 
none In summary, at present it must be stated that the general care 
recommendations that also apply to non-COVID-19 patients 
are initially valid with regard to obstetric anesthesia. 
Nevertheless, the special requirements on the part of hygiene 
and infection protection result in special circumstances that 
should be taken into account when caring for pregnant patients 
from an anesthetic point of view. 









none It is necessary that obstetricians adjust practice to carefully 
weigh the fetal benefits with maternal risks. Therefore, our 













none This is a suggested protocol which may not be applicable to all 
health care settings but can be adapted to local resources and 
limitations of individual L&D units. 




















64 The rate of vertical or peripartum transmission of SARS‐CoV‐
2 is low, if any, for cesarean delivery; no data are available for 
vaginal delivery. Low frequency of spontaneous preterm birth 
and general favorable immediate neonatal outcome are 
reassuring. 





Review Archives of 
Iranian 
medicine 
none The basic strategy for controlling the epidemic is early 
detection, early isolation, early diagnosis and early treatment. 
COVID-19 cases are insidious and transmissible in the 
incubation period, and multiple clusters have been reported in 
China. The causal role of COVID-19 in these cases is therefore 
uncertain and larger studies are needed in the future to describe 
the prevalence, clinical characteristics and course of the 
disease. 








none Outcomes of pregnants delivering in the upcoming months 
will provide more information on this particular new disease 
and its relation to pregnancy. In the meantime, it seems best 
that women should be encouraged to delay becoming pregnant 
until more evidence related to risks associated to COVID-19 
infection during pregnancy is available. In addition, women 
susceptible to be submitted to assisted reproductive technology 
should take some additional precautions as recently 
recommended by La Marca et al. 






and head and neck 
surgery practice. 
Review Head & neck none This review summarizes some of the more readily available 
clinical protocols for head and neck specialists caring for 
patients in an environment of a SARS CoV‐2 mediated 
COVID‐19 pandemic. Recommendations are based largely on 
relatively small series, often from single centers, and national 
position statements. Some represent expert opinion and 
application from experiences with other diseases. 










42 Wu X,  
Radiological 









23 Radiological findings and clinical characteristics in pregnant 
women with COVID-19 were similar to those of non-pregnant 
women with COVID-19. Median absorption time and length 
of hospitalization in asymptomatic patients were significantly 
shorter than in symptomatic patients. Lymphocyte percentage 
and neutrophil granulocyte rate may be used as laboratory 
indicators of CT absorption. 




services among 2 
002 pregnant 








chan ke za zhi 
2002 Pregnant women in Shanghai critically concern about the risk 
of 2019-nCoV infections, and highly demand knowledge and 
measures on prevention and protection from COVID-19. They 
ask for having time-lapse appointments for ANC and online 
access to health information and services. Maternal and child 
care institutes should understand the demands of pregnant 
women, optimize the means of ANC service, and provide 
tailored and accessible health education and service for the 
safety of mother and child. 
44 Sun LL,  
[Perioperative 
management of 
cesarean section for 
pregnant women 
with suspected or 
confirmed COVID-
19]. 
Article in Chinese  
Review Zhonghua fu 
chan ke za zhi 
none It is recommended that the content involves preoperative 
preparation, surgery and anesthesia, postoperative 
management, and issues that need attention. It is for reference 
by fellow practitioners, and I hope it will be helpful. 










45 Pu J,  
[Systematic 
perinatal 
management of the 
pregnant women 
and neonates during 
the epidemic of 
COVID-19]. 
Article in Chinese  
Review Zhonghua fu 
chan ke za zhi 
none This article puts forward targeted suggestions on the whole 
prevention and control of perinatal period for reference. 
46 National Center for 








Article in Chinese 
Review Zhonghua fu 
chan ke za zhi 
none On the basis of more knowledge in this regard, combined with 
the experience from the front line of Wuhan, this article 
recommends the delivery management of pregnant women 
with suspected or confirmed COVID-19, hoping to play a 
greater role in promoting the current obstetric clinical work. 




Care of Infants 
Born to Mothers 








none The manuscript outlines the precautions and steps to be taken 
before, during, and after resuscitation of a newborn born to a 
COVID-19 mother, including three optional variations of 
current standards involving shared-decision making with 
parents for perinatal management, resuscitation of the 
newborn, disposition, nutrition, and postdischarge care. The 
availability of resources may also drive the application of these 
guidelines. 























none Given the challenges of the current coronavirus (SARS-CoV-
2) pandemic and to protect both patients and ultrasound 
providers (physicians, sonographers, allied professionals), the 
International Society of Ultrasound in Obstetrics and 
Gynecology (ISUOG) has compiled the following expert-
opinion-based guidance for the rationalization of ultrasound 
investigations for gynecological indications. 





care and provision 
of ultrasonography 







none This statement provides proposals and options for managing 
patients referred for assessment by early-pregnancy healthcare 
practitioners during the coronavirus disease 2019 (COVID-19) 
pandemic.  
50 Mahony R,  
Pregnancy and 
Sars-Cov-2: A 
Novel Virus in a 
Unique Population 
Comment Irish medical 
journal 
none Comment about “Can SARS-CoV-2 Infection Be Acquired In 
Utero?: More Definitive Evidence Is Needed.”Kimberlin DW. 






summary and short 
report of outcome. 




42 An interim analysis of cases occurring in or transferred to these 
hubs was performed on March 20, 2020 and recommendations 
were released on March 24, 2020. 










52 Chen Y,  
Infants Born to 
Mothers With a 
New Coronavirus 
(COVID-19). 
Case report Frontiers in 
pediatrics 
4 Four full-term, singleton infants were born to pregnant women 
who tested positive for COVID-19 in the city of Wuhan, the 
capital of Hubei province, China, where the disease was first 
identified. Of the three infants, for who consent to be 
diagnostically tested was provided, none tested positive for the 
virus. 








Case report Virologica 
Sinica 
8 Here, we retrospectively analyzed the clinical features, 
laboratory characteristics, and imaging features of eight 
pregnant cases of SARS-CoV-2 infection during the pre-
partum and post-partum periods. Our results showed that four 
of the eight pregnant women were asymptomatic before 
delivery but became symptomatic post-partum. 
54 González Romero 
D, [Pregnancy and 
perinatal outcome 
of a woman with 
COVID-19 
infection]. 
Article in Spanish 
Case report Revista clínica 
española 
1 This article present a case of preganant woman infected by 
SARS-CoV 2.  
They propose some guidelines.  





Review Anesthesia and 
analgesia 
none The goal of this review is to provide evidence-based 
recommendations, or expert opinion when evidence is limited, 
for anesthesiologists caring for pregnant women during the 
COVID 19 pandemic, with a focus on preparedness and best 
clinical obstetric anesthesia practice. 
56 Morand A,  
COVID-19 virus 
and children: What 
do we know? 
Review Archives of 
pediatrics 
none The COVID-19 virus seems to cause benign infections in 
children. The reasons for this tolerance are unknown. 
Currently, it is not clear whether specific pediatric populations 
(children with chronic disease or immunosuppressive 
treatment) will also have such a favorable outcome. 














More liberal testing 
strategy is needed 




1 Potential difficulties in discriminating common complications 
encountered in high-risk pregnancies with comorbidities, such 
as pulmonary edema/embolism, from COVID-19. 
 
 
58 Li N,  
Maternal and 
neonatal outcomes 




Case control Clinical 
infectious 
diseases 
34 Severe maternal and neonatal complications were not observed 
in pregnant women with COVID-19 pneumonia who had 
vaginal delivery or caesarean section. Mild respiratory 
symptoms of pregnant women with COVID-19 pneumonia 
highlight the need of effective screening on admission.  




findings in pregnant 
woman with 
COVID-19 
Case report Ultrasound in 
obstetrics & 
gynecology 
1 Lung-ultrasound examination could play an important role in 
the triage of pregnant women with suspected COVID-19. 
60 Sahu KK,  
A twin challenge to 
handle: COVID‐19 
with pregnancy 
Letter to editor Journal of 
medical 
virology 
13 Pregnancy with COVID‐19 disease is a special scenario that 
































none In response to the World Health Organization (WHO) 
statements and international concerns regarding the 
coronavirus disease 2019 (COVID‐19) outbreak, FIGO has 
issued the following guidance for the management of pregnant 
women at the four main settings of pregnancy: (1) ambulatory 
antenatal care in the outpatient clinics; (2) management in the 
setting of the obstetrical triage; (3) intrapartum management; 
and (4) postpartum management and neonatal care. We also 
provide guidance on the medical treatment of pregnant women 
with COVID‐19 infection. 
62 Liu H,  
Why are pregnant 
women susceptible 
to COVID-19? An 
immunological 
viewpoint 
Review article Journal of 
Reproductive 
Immunology 
18 Pregnant women are more susceptible to respiratory 
pathogens; hence, they may be more susceptible to COVID-19 
infection than the general population. 













none Thus, similar to the difference in the clinical presentation and 
course among SARS, MERS-CoV and COVID-19, there is 
also differences in the outcome and course of pregnant women 
with these coronaviruses’ infection. 










64 Zhang B,  
Treatment with 
convalescent 
plasma for critically 
ill patients with 
SARS-CoV-2 
infection 
Case reports CHEST 4 (including 1 
pregnant 
woman) 
Herein, we presented four critically ill patients with SARS-
CoV-2 infection who received supportive care and 
convalescent plasma. Although all the four patients (including 
a pregnant woman) recovered from SARS-CoV-2 infection 
eventually, randomized trials are needed to eliminate the effect 
of other treatments and investigate the safety and efficacy of 
convalescent plasma therapy. 





of the Italian 
Society of 
Neonatology 
endorsed by the 
Union of European 
Neonatal & 
Perinatal Societies. 
Review article Maternal & 
child nutrition 
none f a mother previously identified as COVID-19 positive or 
under investigation for COVID-19 is asymptomatic or 
paucisymptomatic at delivery, rooming-in is feasible and 
direct breastfeeding is advisable, under strict measures of 
infection control. On the contrary, when a mother with 
COVID-19 is too sick to care for the newborn, the neonate will 
be managed separately and fed fresh expressed breast milk, 
with no need to pasteurize it, as human milk is not believed to 
be a vehicle of COVID-19. 



















Societies of India 
(FOGSI), National 
Neonatology Forum 
of India (NNF), and 






none A set of twenty recommendations are provided under the 
following broad headings: 1) pregnant women with travel 
history, clinical suspicion or confirmed COVID-19 infection; 
2) neonatal care; 3) prevention and infection control; 4) 
diagnosis; 5) general questions. 










Review article Fetal and 
pediatric 
pathology 
none Currently, based on limited data, there is no evidence for 
intrauterine transmission of COVID-19 from infected pregnant 
women to their fetuses. Mothers may be at increased risk for 
more severe respiratory complications. 
68 Panahi L,  
Risks of Novel 
Coronavirus 
Disease (COVID-








none A review of 13 final articles published in this area revealed that 
COVID-19 can cause fetal distress, miscarriage, respiratory 
distress and preterm delivery in pregnant women but does not 
infect newborns. It is necessary to monitor suspected pregnant 
women before and after delivery. For confirmed cases both the 
mother and the newborn child should be followed up 
comprehensively. 










69 Lee DH,  
Emergency 







Case reports Korean journal 
of 
anesthesiology 
1 We report the first case of a SARS-CoV-2 positive woman 
delivering a baby through cesarean section at 37+6 weeks of 
pregnancy in the Republic of Korea. This case suggested that 
negative pressure operating room, skillful medical team, and 
enhanced personal protective equipment including N95 masks, 
surgical cap, double gown, double gloves, shoe covers, and 
powered air-purifying respirator are required at the hospital for 
safe delivery in such a case. 
70 Mirzadeh M,  
Pregnant Women in 
the Exposure to 
COVID-19 
Infection Outbreak: 








none A standard balance in self-care strategies and the adherence to 
diverse training guidelines mentioned in Internet-based guided 
self-help therapy (INSHT) not only can reduce/prevent the 
viral infection in pregnant women, but also can change the 
childbirth mode from cesarean to vaginal. 
71 Zambrano LI,  
A pregnant woman 
with COVID-19 in 
Central America. 




1 On March 9, 2020, a 41-year-old female, who was 31 weeks 
pregnant, were diagnosed with COVID-19. In this case, her 
clinical presentation showed no significant alterations related 
to COVID-19. On March 19, occurred a preterm delivery, 
obtained by spontaneous vaginal delivery. 
72 Chen S,  
Clinical analysis of 
pregnant women 
with 2019 novel 
coronavirus 
pneumonia. 
Case reports Journal of 
medical 
virology 
5 It is probable that pregnant women diagnosed with COVID‐19 
have no fever before delivery. Their primary initial 
manifestations were merely low‐grade postpartum fever or 
mild respiratory symptoms. Therefore, the protective measures 
are necessary on admission; the instant CT scan and real‐time 
reverse‐transcriptase polymerase‐chain‐reaction (RT‐PCR) 
assay should be helpful in early diagnosis and avoid cross‐
infection on the occasion that patients have fever and other 
respiratory signs. 















Review article The Lancet. 
Infectious 
diseases 
none As discussed in the study, although all mothers and 
infants showed good outcomes, all enrolled pregnant 
women were in the third trimester, and all had only mild 
symptoms. Hence, the effect of SARS-CoV-2 infection 
on the fetus in the first or second trimester or in 
patients with moderate to severe infection is unknown.  
We need to further strengthen research to provide an evidence-
based foundation for the medical management of pregnant 
patients with COVID-19. 
74 Yu N,  
Clinical features 
and obstetric and 
neonatal outcomes 
of pregnant patients 
with COVID-19 in 









7 The maternal, fetal, and neonatal outcomes of patients who 
were infected in late pregnancy appeared very good, and these 
outcomes were achieved with intensive, active management 
that might be the best practice in the absence of more robust 
data. The clinical characteristics of these patients with 
COVID-19 during pregnancy were similar to those of non-
pregnant adults with COVID-19 that have been reported in the 
literature. 
75 Qi H,  










none Care should be taken in determination of the timing of 
delivery, assessment of the indications for caesarean section, 
preparation of the delivery room to prevent infection, choice 
of the type of anesthesia, and newborn management. 
76 Chen Y,  
Maternal health 
care management 




Case reports Journal of 
medical 
virology 
3 Given that 420 patients were diagnosed by Mar. 11th in 
Shenzhen and tens of cases was diagnosed in our hospital, yet 
no nosocomial infection has occurred and none of the pregnant 
woman registered in our hospital was reported to be infected, 
this management should be effective to an extant, however 
mathematical model may be needed to quantify the 
effectiveness of these methods.  

























none On January 28, we published “Guidance for maternal and fetal 
management during pneumonia epidemics of novel 
coronavirus infection in the Wuhan Tongji Hospital (First 
edition)”[4]. Based on the clinical characteristics, diagnosis 
and treatment progress of the recently discovered diseases, we 
offered an updated clinical management for pregnant women 
and newborns with NCP. 











none Special precautions are required to minimize cross-infection of 
healthcare providers while performing procedures that require 
close physical contact and promote droplet exposure such as 
vaginal delivery. Much of the obstetric management is based 
on consensus and best practice recommendations as clinical 
efficacy data regarding anti-viral therapy and corticosteroid 
use is evolving. 





Responding to a 
Rapidly Evolving 
Situation. 
Review article Obstetrics and 
gynecology 
none Some current recommendations are well supported, based 
largely on what we know from seasonal influenza: patients 
should avoid contact with ill persons, avoid touching their 
face, cover coughs and sneezes, wash hands frequently, 
disinfect contaminated surfaces, and stay home when sick. 
Prenatal clinics should ensure all pregnant women and their 
visitors are screened for fever and respiratory symptoms, and 
symptomatic women should be isolated from well women and 
required to wear a mask. 










80 Liao X,  
Chest CT Findings 
in a Pregnant 
Patient with 2019 
Novel Coronavirus 
Disease. 
Case report Balkan 
medical 
journal 
1 In this report, the chest CT characteristics of a pregnant woman 
with COVID-19 are presented from admission to recovery. 
The patient showed mild clinical symptoms. She was 
confirmed to have COVID-19 based on a positive nucleic acid 
test and typical viral infection signs in the lungs observed by 
CT. The observations in this case suggested that the clinical 
symptoms of COVID-19 can be inconsistent with the CT 
examination results. 








Review article Emergency 
medicine 
practice 
none Clearly, larger studies will need to be conducted to better 
evaluate the risk of vertical transmission between mother and 
fetus with SARS-CoV-2 infection. 
82 Kang X,  
Anesthesia 
management in 
cesarean section for 
a patient with 
coronavirus disease 
2019 





1 For ordinary COVID-19 patients intraspinal anesthesia is 
preferred in cesarean section, and the influence on respiration 
and circulation in both maternal and infant should be reduced; 
while for severe or critically ill patients general anesthesia with 
endotracheal intubation should be adopted. The safety of 
medical environment should be ensured, and level-Ⅲ standard 
protection should be taken for anesthetists. Special attention 
and support should be given to maternal psychology. 
83 Moro F,  
How to perform 





Review article Ultrasound in 
obstetrics & 
gynecology 
none We propose a practical approach for 
obstetricians/gynecologists to perform lung ultrasound, 
showing potential applications, semiology and practical 
aspects, which should be of particular importance in 
emergency situations, such as the current pandemic infection 
of COVID-19. 










84 Rimmer A,  
Covid-19: doctors 
in final trimester of 
pregnancy should 







none Women who are more than 28 weeks pregnant should avoid 
direct contact with patients—whether or not they could be 
infected with covid-19, says updated guidance. The advice 
comes from updated guidance from the Royal College of 
Obstetricians and Gynaecologists (RCOG), the Royal College 
of Midwives, and the Royal College of Paediatrics and Child 
Health.  
 














none Pregnancy is known as a period at higher risk for the 
consequences of respiratory infections, as for influenza, so it 
seems important to screen for Covid-19 in the presence of 
symptoms and to monitor closely pregnant women. In this 
context of the SARS-Covid-2 epidemic, the societies of 
gynecology-obstetrics, infectious diseases and neonatalogy 
have proposed a French protocol for the management of 
possible and proven cases of SARS-Covid-2 in pregnant 
women. 
86 Wen R,  









1 A 31-year-old female at 30 weeks gestation presented with 
mild diarrhea (2-3 times a day) for one day. Combined PCR 
and CT, she was diagnosed as pregnancy with COVID-19. She 
made a recovery and discharged on Feb 20. The fetus 
developed normally and wasn’t birth during hospitalization. 
87 Schmid MB,  
COVID-19 in 
pregnant women. 
Review article The Lancet. 
Infectious 
disease 
none Therefore, as long as national authority guidelines or evidence-
based recommendations do not yet exist, clinical practitioners 
need to screen the literature and review their actions on a daily 
basis. 
88 Baud D,  
COVID-19 in 







none We therefore updated the guidelines according to the data 
available at the beginning of March, 2020 (appendix). It is our 
responsibility, as specialists working in different fields of 
perinatology, to improve our own recommendations and that 
of others for the benefit of our patients. 










89 [Perinatal and 
neonatal 
management plan 











none The Working Group for the Prevention and Control of 
Neonatal SARS-CoV-2 Infection in the Perinatal Period of the 
Editorial Committee of Chinese Journal of Contemporary 
Pediatrics worked out the perinatal and neonatal management 
plan for prevention and control of SARS-CoV-2 infection (1st 
Edition). 
90 Wang LS,  















none Perinatal and neonatal management plan for prevention and 
control of SARS-CoV-2 infection (2nd Edition) has been 
worked out by the Editorial Committee of Chinese Journal of 
Contemporary Pediatrics. 




and neonates born 












none Ten key recommendations were provided for the management 
of COVID‐19 infections in pregnancy. 










92 Zhou D,  
COVID-19: a 
recommendation to 
examine the effect 
of 
hydroxychloroquin
e in preventing 
infection and 
progression. 




none In summary, we propose that hydroxychloroquine (HCQ) 
could serve as a better therapeutic approach than chloroquine 
(CQ) for the treatment of SARS-CoV-2 infection. There are 
three major reasons for this: (i) HCQ is likely to attenuate the 
severe progression of COVID-19 through inhibiting the 
cytokine storm by reducing CD154 expression in T cells; (ii) 
HCQ may confer a similar antiviral effect at both pre- and 
post- infection stages, as found with CQ; (iii) HCQ has fewer 
side effects, is safe in pregnancy and is cheaper and more 
highly available in China. 
93 Sahu KK,  
COVID-2019 and 
Pregnancy: A plea 
for transparent 
reporting of all 
cases. 




none Transparent and comprehensive reporting of all cases of 
COVID-19 pregnancies is very important. We believe that 
building a common portal where details of all such cases could 
be entered continuously so that data analysis couls be 
performed in real-time to get some concrete results helping to 
generate evidence and guide clinical management.  










none Government guidance advises people with an increased risk 
of severe illness from covid-19, including pregnant women, 
to be particularly stringent in following social distancing 
measures. No data currently suggest an increased risk of 
miscarriage or early pregnancy loss in relation to covid-19. 
 
95 Liu D,  
Pregnancy and 
Perinatal Outcomes 
of Women With 
Coronavirus 
Disease (COVID-
19) Pneumonia: A 
Preliminary 
Analysis. 
Review article American 
journal of 
roentgenology 
15 Pregnancy and childbirth did not aggravate the course of 
symptoms or CT features of COVID-19 pneumonia. All the 
cases of COVID-19 pneumonia in the pregnant women in our 
study were the mild type. All the women in this study—some 
of whom did not receive antiviral drugs—achieved good 
recovery from COVID-19 pneumonia. 














Pregnancy; a Letter 
to Editor. 




none Increasing mothers' awareness about the transmission of 
Coronavirus, risk factors, and red flags, as well as providing 
tele-counseling for pregnancy care and tele-triage could help 
reduce their anxiety and worry. It is also recommended that in 
cities where home birth and home services after birth are 
available, the medical team provide these services at home 
while maintaining safety. 





CoV-2: Should We 
Worry? 
Case reports Clinical 
infectious 
diseases 
2 We presented two cases of COVID-19 associated SARS-CoV-
2 infection during third trimester of pregnancy. Both mothers 
and newborns had excellent outcomes. We failed to identify 
SARS-CoV-2 in all the products of conception and the 
newborns. This report provided evidence of low risk of 
intrauterine infection by vertical transmission of SARS-CoV-
2. 
98 Jiao J,  
Under the epidemic 
situation of 
COVID-19, should 
special attention to 
pregnant women be 
given? 
Review article Journal of 
medical 
virology 
none More data and experience is still needed to be collected for 
confirming the transmission and clinical characteristics of 
pregnancy. There is no recommendation for routine detection 
and monitoring of early and midterm pregnancy, but such 
follow ups may need to be further strengthened. Pregnant 
medical staff should be supported by policy.  










99 Schwartz DA,  

















38 This analysis reveals that unlike coronavirus infections of 
pregnant women caused by SARS and MERS, in these 38 
pregnant women COVID-19 did not lead to maternal deaths. 
Importantly, and similar to pregnancies with SARS and 
MERS, there were no confirmed cases of intrauterine 
transmission of SARS-CoV-2 from mothers with COVID-19 
to their fetuses. All neonatal specimens tested, including in 
some cases placentas, were negative by rt-PCR for SARS-
CoV-2. At this point in the global pandemic of COVID-19 
infection there is no evidence that SARSCoV-2 undergoes 
intrauterine or transplacental transmission from infected 
pregnant women to their fetuses. 





Review article Ultrasound in 
obstetrics & 
gynecology 
32 Serious morbidity occurred in 2/32 women with COVID-19, 
both of whom required ICU care. Compared with SARS and 
MERS, COVID-19 appears less lethal, acknowledging the 
limited number of cases reported to date and that one woman 
remains in a critical condition. Preterm delivery affected 47% 
of women hospitalized with COVID-19. Based on this review, 
RCOG, in consultation with RCPCH, developed guidance for 
delivery and neonatal care in pregnancies affected by COVID-
19, which recommends that delivery mode be determined 
primarily by obstetric indication and recommends against 
routine separation of affected mothers and their babies. 










101 Chen R,  
Safety and efficacy 
of different 
anesthetic regimens 
for parturients with 
COVID-19 
undergoing 
Cesarean delivery: a 
case series of 17 
patients. 
Case reports Canadian 
journal of 
anaesthesia 
17 Both epidural and general anesthesia were safely used for 
Cesarean delivery in the parturients with COVID-19. 
Nevertheless, the incidence of hypotension during epidural 
anesthesia appeared excessive. Proper patient transfer, medical 
staff access procedures, and effective biosafety precautions are 
important to protect medical staff from COVID-19. 
102 Liu H,  
Clinical and CT 
imaging features of 
the COVID-19 
pneumonia: Focus 
on pregnant women 
and children. 










Atypical clinical findings of pregnant women with COVID-19 
could increase the difficulty in initial identification. 
Consolidation on CT was more common in the pregnant 
groups. The clinically-diagnosed cases were vulnerable to 
more pulmonary involvement. CT was the modality of choice 
for early detection, severity assessment, and timely therapeutic 
effects evaluation for the cases with epidemic and clinical 
features of COVID-19 with or without laboratory 
confirmation. 
103 Wang S,  
A case report of 
neonatal COVID-
19 infection in 
China. 
Case reports Clinical 
Infectious 
Disease 
1 We report the first case of neonatal SARS-CoV-2 infection in 
China where the mother was confirmed with COVID-19. The 
clinical manifestations of the mother and the baby were both 
mild and the baby’s prognosis was good. Whether the case is 
intrauterine vertical transmission or not remains controversial. 




Review article Nature 
medecine 
none Chen et al. studied nine pregnant women with lab-confirmed 
COVI-19 who were admitted to the Zhongnan Hospital of 
Wuhan University. They found that their clinical symptoms 
were similar to those of non-pregnant adults and that there was 
no indication of vertical transmission to children, although the 
findings need to be confirmed in a larger study. 










105 Poon LC,  
ISUOG Interim 













none In response to the World Health Organization (WHO) 
statements and international concerns regarding the novel 
coronavirus infection (COVID‐19) outbreak, the International 
Society of Ultrasound in Obstetrics and Gynecology (ISUOG) 
is issuing the following guidance for management during 
pregnancy and puerperium. 
106 Zhu H,  
Clinical analysis of 
10 neonates born to 
mothers with 2019-
nCoV pneumonia. 




Perinatal 2019-nCoV infection may have adverse effects on 
newborns, causing problems such as fetal distress, premature 
labor, respiratory distress, thrombocytopenia accompanied by 
abnormal liver function, and even death. However, vertical 
transmission of 2019-nCoV is yet to be confirmed. 







infection in nine 
pregnant women: a 
retrospective 
review of medical 
records. 
Case reports The Lancet 9 The clinical characteristics of COVID-19 pneumonia in 
pregnant women were similar to those reported for non-
pregnant adult patients who developed COVID-19 pneumonia. 
Findings from this small group of cases suggest that there is 
currently no evidence for intrauterine infection caused by 
vertical transmission in women who develop COVID-19 
pneumonia in late pregnancy. 
108 Qiao J,  




Comment The Lancet none Pregnant women and newborn babies should be considered 
key at-risk populations in strategies focusing on prevention 
and management of COVID-19 infection. 
 










109 Zhang L, [Analysis 
of the pregnancy 
outcomes in 
pregnant women 
with COVID-19 in 
Hubei Province]. 
Article in Chinese. 
Case reports Zhonghua fu 
chan ke za zhi 
10  
(neonates) 
If there is an indication for obstetric surgery or critical illness 
of COVID-19 in pregnant women, timely termination of 
pregnancy will not increase the risk of premature birth and 
asphyxia of the newborn, but it is beneficial to the treatment 
and rehabilitation of maternal pneumonia. Preventive use of 
long-acting uterotonic agents could reduce the incidence of 
postpartum hemorrhage during surgery. 2019-nCoV infection 
has not been found in neonates deliverd from pregnant women 
with COVID-19. 






Case reports Journal of 
infection 
13 The report showed pregnant women are also susceptible to 
SARS-CoV-2 infection. SARS-CoV-2 may increase health 
risks to both mothers and infants during pregnancy. Efforts 
should be taken to reduce the infection rate of SARS-CoV-2 
both in pregnant and perinatal period, and more intensive 
attention should be paid to pregnant patients. 
 











none Pregnant women with laboratory-confirmed SARS-CoV-2 
infection who are asymptomatic should be self-monitored at 
home for clinical features of COVID-19 for at least 14 days. 
Newborns of mothers positive for SARS-CoV-2 should be 
isolated for at least 14 days or until viral shedding clears, 
during which time direct breastfeeding is not recommended. 
112 Liang H,  
Novel corona virus 
disease (COVID-










none A multi‐disciplinary team approach should be adopted in 
managing these patients as it allows to effectively share the 
expertise as well as responsibility, and treat our patients with 
dignity and compassion. In hospitals, the transmission of the 
virus and deaths among healthcare professionals are serious 
concerns. Improving healthcare governance, as well as 
supporting, educating and training healthcare personnel in 
infection control and self‐protection need to be prioritized. 






















none Perinatal infection can occur if the baby is born to a pregnant 
woman with confirmed infection via vaginal delivery. 
114 Li Y,  







Case report Emerging 
infectious 
diseases 
1 A woman with 2019 novel coronavirus disease in her 35th 
week of pregnancy delivered an infant by cesarean section in 
a negative-pressure operating room. The infant was negative 
for severe acute respiratory coronavirus 2. This case suggests 
that mother-to-child transmission is unlikely for this virus. 




Review article Ultrasound in 
obstetrics & 
gynecology 
none Currently, there is no evidence that pregnant women are more 
susceptible to COVID‐19 infection and that those with 
COVID‐19 infection are more prone to developing severe 
pneumonia. There is also no evidence of vertical mother‐to‐
baby transmission of COVID‐19 infection when the maternal 
infection manifests in the third trimester. 
116 Zaigham M,  
Maternal and 
Perinatal Outcomes 
with COVID-19: a 
systematic review 
of 108 pregnancies. 




108 Although the majority of mothers were discharged without any 
major complications, severe maternal morbidity as a result of 
COVID-19 and perinatal deaths were reported. Vertical 
transmission of the COVID-19 could not be ruled out. Careful 
monitoring of pregnancies with COVID-19 and measures to 
prevent neonatal infection are warranted. 










117 Wang X,  
A case of 2019 
Novel Coronavirus 
in a pregnant 
woman with 
preterm delivery. 
Case report Clinical 
infectious 
diseases 
1 In this case, we reported that a mother with COVID-19 gave 
birth to a healthy baby with no evidence of 
COVID-19 during her 30 weeks pregnancy. Our case ended up 
with an uneventful postpartum and neonatal 
course. The RT-PCR tests were all negative, suggesting the 
infant was unaffected by COVID-19, and all 
healthcare workers taking care of him had remained 
asymptomatic. 








analysis of three 
cases]. Article in 
Chinese.  
Case reports Chinese 
journal of 
pathology 
3 The clinical characteristics of pregnant women with 2019-
nCoV infection in late pregnancy are similar to those of non-
pregnant patients, and no severe adverse pregnancy outcome 
is found in the 3 cases of our observation. Pathological study 
suggests that there are no morphological changes related to 
infection in the three placentas. Currently no evidence for 
intrauterine vertical transmission of 2019-nCoV is found in the 
three women infected by 2019-nCoV in their late pregnancy. 











none Principles of management of coronavirus disease 2019 in 
pregnancy include early isolation, aggressive infection control 
procedures, oxygen therapy, avoidance of fluid overload, 
consideration of empiric antibiotics (secondary to bacterial 
infection risk), laboratory testing for the virus and coinfection, 
fetal and uterine contraction monitoring, early mechanical 
ventilation for progressive respiratory failure, individualized 
delivery planning, and a team-based approach with 
multispecialty consultations. 










120 Catton H,  
Global challenges 
in health and health 
care for nurses and 
midwives 
everywhere. 
Review article International 
nursing review 
none The next decade is likely to produce any number of global 
challenges that will affect health and health care, including 
pan‐national infections such as the new coronavirus COVID‐
19 and others that will be related to global warming. Nurses 
will be required to react to these events, even though they will 
also be affected as ordinary citizens. The future resilience of 
healthcare services will depend on having sufficient numbers 
of nurses who are adequately resourced to face the coming 
challenges. 
121 Working Group for 
the Prevention and 
Control of Neonatal 
2019-nCoV 
Infection in the 
Perinatal Period of 
the Editorial 
Committee of 






for prevention and 
control of 2019 
novel coronavirus 
infection (1st 








none According to the latest 2019-nCoV national management plan 
and the actual situation, the Working Group for the Prevention 
and Control of Neonatal 2019-nCoV Infection in the Perinatal 
Period of the Editorial Committee of Chinese Journal of 
Contemporary Pediatrics puts forward recommendations for 
the prevention and control of 2019-nCoV infection in 
neonates. 























Review article Viruses none In order to assess the potential of the Wuhan 2019-nCoV to 
cause maternal, fetal and neonatal morbidity and other poor 
obstetrical outcomes, this communication reviews the 
published data addressing the epidemiological and clinical 
effects of SARS, MERS, and other coronavirus infections on 
pregnant women and their infants. 




Review article The Lancet none Considering that the 2019-nCoV seems to have a similar 
pathogenic potential as SARS-CoV and MERS-CoV, pregnant 
women are at increased risk of severe infections, there are no 
specific clinical signs of coronavirus infections preceding 
severe complications, coronaviruses have the potential to 
cause severe maternal or perinatal adverse outcomes, or both, 
and the current lack of data on the consequences of a 2019-
nCoV infection during pregnancy, we recommend systematic 
screening of any suspected 2019-nCoV infection during 
pregnancy. 






















Review article Pathogens none NOT ABOUT CORONAVIRUS – 2 
Porcine epidemic diarrhea virus (PEDV) is a highly virulent 
re-emerging enteric coronavirus that causes acute diarrhea, 
dehydration, and up to 100% mortality in neonatal suckling 
piglets. Because pregnancy-associated immune alterations 
influence viral pathogenesis and adaptive immune responses 
in many different species, a better understanding of host 
immune responses to PEDV in pregnant swine may translate 
into improved maternal immunization strategies against 
enteric pathogens for multiple species. 







Rational Design of 
Live Attenuated 
Vaccines. 




none NOT ABOUT CORONAVIRUS – 2 
PEDV belongs to the genus Alphacoronavirus within the 
family Coronaviridae.  
n the future, rationally designed PEDV LAV candidates 
bearing different genetic modifications should be evaluated in 
pregnant sows that are the major targets of PEDV vaccination, 
and can passively protect suckling piglets from PEDV disease 
via the PEDV-specific neutralizing antibodies in colostrum 
and milk. 





emboli in a 
pregnant woman 
with coronavirus. 
Case report IDCases 1 The patient’s presentation reinforces that neurological 
symptoms may be the presenting complaint in patients with 
endocarditis. Clinicians should maintain a high index of 
suspicion for IE when encountering patients presenting with 
neurological complaints in the setting of fever, given the 
potential for cerebrovascular complications, and the improved 
outcomes with timely initiation of appropriate antimicrobial 
therapy. 










127 Won H,  
Generation and 
protective efficacy 
of a cold-adapted 
attenuated genotype 
2b porcine epidemic 
diarrhea virus. 
Review article Journal of 
veterinary 
science 
none NOT ABOUT CORONAVIRUS – 2 
Porcine epidemic diarrhea virus (PEDV) is a member of the 
genus Alphacoronavirus, belonging to in the family 
Coronaviridae of the order Nidovirales. 
This is the first report describing the development of a cold-
adapted MLV vaccine based on a virulent G2b PEDV strain. 











Review article Letters in 
applied 
microbiology 
none NOT ABOUT CORONAVIRUS – 2 
Porcine epidemic diarrhoea virus (PEDV) causes severe 
diarrhoea in neonatal suckling piglets with a high mortality. 
Our data show that pregnant sows were immunized with 
'coated PEDV-loaded microspheres + killed PEDV vaccines' 
(heterologous prime-boost immunization) could protect more 
than 90% suckling piglets delivered by the sows against the 
virus. These findings provide a new model of developing safe 
and effective immunizations for newborn animals against 
established and emerging enteric infections. 














Review article PloS one none NOT ABOUT CORONAVIRUS – 2 
The porcine epidemic diarrhoea virus (PEDV) devastates the 
health of piglets but may not infect piglets whose CMP-N-
glycolylneuraminic acid hydroxylase (CMAH) gene is 
mutated (knockouts, KO) by using CRISPR/Cas9 gene editing 
techniques. These results suggest that porcine CMAH KO with 
nullified NGNA expression are not immune to PEDV but that 
this KO may lessen the severity of the infection and delay its 
occurrence. 


















Review article ACS applied 
materials & 
interfaces 
none NOT ABOUT CORONAVIRUS – 2 
Middle East respiratory syndrome coronavirus (MERS-CoV) 
causes a severe acute respiratory syndrome-like illness with 
high pathogenicity and mortality due to the lack of effective 
therapeutics.In summary, PIH-AuNRs represent a novel class 
of antiviral agents and have a great potential in treating MERS 
in the clinic. 
131 Jang G,  
Assessment of the 
safety and efficacy 
of an attenuated live 
vaccine based on 
highly virulent 
genotype 2b porcine 
epidemic diarrhea 
virus in nursing 
piglets. 
Review article Veterinary 
microbiology 
none NOT ABOUT CORONAVIRUS – 2 
We have previously reported the generation of the attenuated 
KNU-141112-S DEL5/ORF3 virus by continuous propagation 
of highly virulent G2b porcine epidemic diarrhea virus 
(PEDV) in Vero cells. 
The data demonstrated that the attenuated S DEL5/ORF3 
strain guarantees the safety to host animals with no reversion 
to virulence and is suitable as an effective primary live vaccine 
providing durable maternal lactogenic immunity for passive 
piglet protection. 





virus PC22A strain 
in conventional 
weaned pigs. 
Review article BMC 
veterinary 
research 
none NOT ABOUT CORONAVIRUS – 2 
Therefore, P100C4 potentially could be tested as a priming 
vaccine or be further modified using reverse genetics. It also 
can be administered in multiple doses or be combined with 
inactivated or subunit vaccines and adjuvants as a PEDV 
vaccination regimen, whose efficacy can be tested in the 
future. 


















of two cases & 








2 NOT ABOUT CORONAVIRUS – 2 
The overall case fatality rate remains high and is comparable 
to the overall case fatality rates. The disease had also resulted 
in fetal demise in 27% of cases. 





pediatrics: a report 
of seven cases from 
Saudi Arabia. 
Case reports Frontiers of 
medicine 
7 NOT ABOUT CORONAVIRUS – 2 
MERS-CoV remains an uncommon disease among 
children, and its course follows a milder path among 
children than those of adults. Majority of cases were 
asymptomatic and were diagnosed during the course of 
contact investigation. 
135 Giersing BK,  













Vaccine none NOT ABOUT CORONAVIRUS – 2 
 





















45 cows NOT ABOUT CORONAVIRUS – 2 
IFN-based drugs enhance the protective effect of vaccination 
against associative infections in the newborn calves. They 
stimulate a rise in the titer of antibodies to Rotavirus, 
coronavirus, VD, and mucosal disease complex as well as an 
increase in immunoglobulins A, M, and G. 
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